JP2022532556A5 - - Google Patents
Info
- Publication number
- JP2022532556A5 JP2022532556A5 JP2021566149A JP2021566149A JP2022532556A5 JP 2022532556 A5 JP2022532556 A5 JP 2022532556A5 JP 2021566149 A JP2021566149 A JP 2021566149A JP 2021566149 A JP2021566149 A JP 2021566149A JP 2022532556 A5 JP2022532556 A5 JP 2022532556A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- domain
- polypeptide
- item
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025020891A JP2025081414A (ja) | 2019-05-08 | 2025-02-12 | Ｃｌｌ－１標的免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845306P | 2019-05-08 | 2019-05-08 | |
| US62/845,306 | 2019-05-08 | ||
| PCT/US2020/031781 WO2020227475A1 (en) | 2019-05-08 | 2020-05-07 | Cll-1 targeted immunotherapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020891A Division JP2025081414A (ja) | 2019-05-08 | 2025-02-12 | Ｃｌｌ－１標的免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532556A JP2022532556A (ja) | 2022-07-15 |
| JP2022532556A5 true JP2022532556A5 (https=) | 2023-05-15 |
Family
ID=73051177
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566149A Pending JP2022532556A (ja) | 2019-05-08 | 2020-05-07 | Ｃｌｌ－１標的免疫療法 |
| JP2025020891A Pending JP2025081414A (ja) | 2019-05-08 | 2025-02-12 | Ｃｌｌ－１標的免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020891A Pending JP2025081414A (ja) | 2019-05-08 | 2025-02-12 | Ｃｌｌ－１標的免疫療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12421315B2 (https=) |
| EP (1) | EP3966249A4 (https=) |
| JP (2) | JP2022532556A (https=) |
| KR (1) | KR20220031549A (https=) |
| CN (1) | CN114502586B (https=) |
| AU (1) | AU2020267639A1 (https=) |
| BR (1) | BR112021022365A2 (https=) |
| CA (1) | CA3148027A1 (https=) |
| IL (1) | IL287769A (https=) |
| MA (1) | MA55905A (https=) |
| MX (1) | MX2021013590A (https=) |
| SG (1) | SG11202111927QA (https=) |
| WO (1) | WO2020227475A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210104772A (ko) | 2018-12-14 | 2021-08-25 | 블루버드 바이오, 인코포레이티드. | 이량체화제로 조절된 면역수용체 복합체 |
| BR112021020999A2 (pt) * | 2019-05-04 | 2021-12-14 | Inhibrx Inc | Polipeptídeos de ligação à clec12a e usos dos mesmos |
| KR20220031549A (ko) | 2019-05-08 | 2022-03-11 | 2세븐티 바이오, 인코포레이티드 | Cll-1 표적화 면역요법 |
| CA3255500A1 (en) * | 2022-04-08 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | MULTI-PART RECEIVERS AND SIGNALING COMPLEXES |
| JP2025520227A (ja) | 2022-05-26 | 2025-07-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | レンチウイルスベクターを維持するための組成物及びその使用 |
| CN115772222B (zh) * | 2022-12-16 | 2024-03-29 | 浙江康佰裕生物科技有限公司 | 抗cll1单域抗体及其应用 |
| KR102908421B1 (ko) | 2025-04-16 | 2026-01-12 | (주)주인정보시스템 | 인공지능 기반 빌딩 자동제어 시스템 및 그 방법 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291161B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| DE69309472T2 (de) | 1992-01-23 | 1997-10-23 | Merck Patent Gmbh, 64293 Darmstadt | Fusionsproteine von monomeren und dimeren von antikörperfragmenten |
| US6972193B1 (en) | 1993-02-12 | 2005-12-06 | Board Of Trustees Of Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
| EP0804561B1 (en) | 1993-02-12 | 2009-12-30 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
| ATE277081T1 (de) | 1994-01-11 | 2004-10-15 | Dyax Corp | Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| JP2002508971A (ja) | 1998-01-15 | 2002-03-26 | アリアド・ジーン・セラピューティクス・インコーポレーテッド | 多量体キメラ蛋白質を使用する生物学的イベントの調節 |
| JP2002503667A (ja) | 1998-02-13 | 2002-02-05 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 新規な二量体化剤、その製造および使用 |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| EP1699826B1 (en) | 2005-01-05 | 2009-03-11 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| WO2010062966A2 (en) | 2008-11-26 | 2010-06-03 | The General Hospital Corporation | Methods for inducing mixed chimerism |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| US9233125B2 (en) | 2010-12-14 | 2016-01-12 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer |
| HUE042040T2 (hu) | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
| DK2956175T3 (da) | 2013-02-15 | 2017-11-27 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
| CA2904236A1 (en) | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Heparanase expression in t lymphocytes |
| EP3925618A1 (en) | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| EP3087101B1 (en) * | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| ES2857226T3 (es) * | 2014-03-15 | 2021-09-28 | Novartis Ag | Receptor de antígeno quimérico regulable |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| SG10201913782UA (en) * | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| ES2846881T3 (es) * | 2015-05-01 | 2021-07-30 | Inhibrx Inc | Moléculas que se dirigen al sistema de secreción de tipo III |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| EP3341410B1 (en) * | 2015-08-24 | 2021-06-02 | Cellectis | Chimeric antigen receptors with integrated controllable functions |
| MA55746A (fr) | 2016-01-21 | 2022-03-02 | Novartis Ag | Molécules multispécifiques ciblant cll-1 |
| EP3443002A4 (en) | 2016-04-14 | 2019-12-04 | Bluebird Bio, Inc. | SYSTEMS FOR RECOVERED CHIMERIC ANTIGEN RECEPTORS |
| CA3084551A1 (en) | 2017-12-14 | 2019-06-20 | Bluebird Bio, Inc. | Daric interleukin receptors |
| CN111819682B (zh) | 2018-03-26 | 2025-04-29 | 三菱综合材料株式会社 | 绝缘电路基板用接合体的制造方法及绝缘电路基板用接合体 |
| EP3850013A4 (en) | 2018-09-10 | 2022-10-05 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF |
| WO2020113063A1 (en) | 2018-11-30 | 2020-06-04 | Aleta Biotherapeutics Inc. | Single domain antibodies against cll-1 |
| US20240025963A1 (en) | 2018-12-14 | 2024-01-25 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| KR20210104772A (ko) | 2018-12-14 | 2021-08-25 | 블루버드 바이오, 인코포레이티드. | 이량체화제로 조절된 면역수용체 복합체 |
| US20240034768A1 (en) | 2018-12-14 | 2024-02-01 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| WO2020123947A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| BR112021020999A2 (pt) | 2019-05-04 | 2021-12-14 | Inhibrx Inc | Polipeptídeos de ligação à clec12a e usos dos mesmos |
| MA55910A (fr) | 2019-05-08 | 2022-03-16 | 2Seventy Bio Inc | Immunothérapies ciblant cd123 |
| KR20220031549A (ko) | 2019-05-08 | 2022-03-11 | 2세븐티 바이오, 인코포레이티드 | Cll-1 표적화 면역요법 |
| AU2020359530A1 (en) | 2019-09-30 | 2022-05-19 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| US12454580B2 (en) | 2020-04-10 | 2025-10-28 | Regeneron Pharmaceuticals, Inc. | FRB antibodies |
| JP2024525727A (ja) | 2021-07-14 | 2024-07-12 | ２セブンティ バイオ インコーポレイテッド | 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体 |
-
2020
- 2020-05-07 KR KR1020217039632A patent/KR20220031549A/ko active Pending
- 2020-05-07 JP JP2021566149A patent/JP2022532556A/ja active Pending
- 2020-05-07 MA MA055905A patent/MA55905A/fr unknown
- 2020-05-07 EP EP20801987.7A patent/EP3966249A4/en active Pending
- 2020-05-07 AU AU2020267639A patent/AU2020267639A1/en active Pending
- 2020-05-07 WO PCT/US2020/031781 patent/WO2020227475A1/en not_active Ceased
- 2020-05-07 BR BR112021022365A patent/BR112021022365A2/pt unknown
- 2020-05-07 MX MX2021013590A patent/MX2021013590A/es unknown
- 2020-05-07 SG SG11202111927QA patent/SG11202111927QA/en unknown
- 2020-05-07 US US17/608,738 patent/US12421315B2/en active Active
- 2020-05-07 CA CA3148027A patent/CA3148027A1/en active Pending
- 2020-05-07 CN CN202080049880.5A patent/CN114502586B/zh active Active
-
2021
- 2021-11-01 IL IL287769A patent/IL287769A/en unknown
-
2025
- 2025-02-12 JP JP2025020891A patent/JP2025081414A/ja active Pending
- 2025-08-27 US US19/311,186 patent/US20260055192A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532556A5 (https=) | ||
| JP2022531719A5 (https=) | ||
| CN113784733B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| JP7068459B2 (ja) | Ｎｙｅｓｏ ｔｃｒ | |
| JP6336684B2 (ja) | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 | |
| Bartkowiak et al. | 4-1BB agonists: multi-potent potentiators of tumor immunity | |
| JP2025511872A5 (https=) | ||
| Tang et al. | T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo | |
| CN111051502B (zh) | 通用型嵌合抗原受体t细胞制备技术 | |
| JP2022532557A5 (https=) | ||
| EP3250695A1 (en) | Universal immune cells for cancer immunotherapy | |
| EP2632482A2 (en) | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies | |
| JP2022537159A5 (https=) | ||
| Pircher et al. | T cell engineering | |
| JP2022513460A5 (https=) | ||
| CN110257338B (zh) | 嵌合细胞因子受体 | |
| WO2017024440A1 (zh) | 含Toll样受体胞内结构域的嵌合抗原受体 | |
| CN117844761A (zh) | 逆转肿瘤微环境的融合蛋白及其应用 | |
| Wu et al. | Immunotherapies: the blockade of inhibitory signals | |
| JP2025513801A5 (https=) | ||
| RU2020122708A (ru) | Рецепторы nkg2d daric | |
| JP2025081414A5 (https=) | ||
| CN113330038A (zh) | Cd20组合靶向的工程化免疫细胞 | |
| JP2017081836A (ja) | 細胞傷害性ｔ細胞の作製方法 | |
| Voutsadakis | Immune ligands for cytotoxic T Lymphocytes (CTLS) in cancer stem cells (CSCS) |